JP6928083B2 - Ｐｄ−１ペプチド阻害剤 - Google Patents

Ｐｄ−１ペプチド阻害剤 Download PDF

Info

Publication number
JP6928083B2
JP6928083B2 JP2019515467A JP2019515467A JP6928083B2 JP 6928083 B2 JP6928083 B2 JP 6928083B2 JP 2019515467 A JP2019515467 A JP 2019515467A JP 2019515467 A JP2019515467 A JP 2019515467A JP 6928083 B2 JP6928083 B2 JP 6928083B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
peptide consisting
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019515467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531293A (ja
JP2019531293A5 (enExample
Inventor
ガブリエル エム． グティエレス，
ガブリエル エム． グティエレス，
ヴィナヤカ コトライア，
ヴィナヤカ コトライア，
ジェイムズ パヌッチ，
ジェイムズ パヌッチ，
ラムセス アヤラ，
ラムセス アヤラ，
Original Assignee
レイドス， インコーポレイテッド
レイドス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レイドス， インコーポレイテッド, レイドス， インコーポレイテッド filed Critical レイドス， インコーポレイテッド
Publication of JP2019531293A publication Critical patent/JP2019531293A/ja
Publication of JP2019531293A5 publication Critical patent/JP2019531293A5/ja
Application granted granted Critical
Publication of JP6928083B2 publication Critical patent/JP6928083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019515467A 2016-09-15 2017-09-15 Ｐｄ−１ペプチド阻害剤 Active JP6928083B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395195P 2016-09-15 2016-09-15
US62/395,195 2016-09-15
PCT/US2017/051697 WO2018053218A1 (en) 2016-09-15 2017-09-15 Pd-1 peptide inhibitors

Publications (3)

Publication Number Publication Date
JP2019531293A JP2019531293A (ja) 2019-10-31
JP2019531293A5 JP2019531293A5 (enExample) 2020-11-05
JP6928083B2 true JP6928083B2 (ja) 2021-09-01

Family

ID=60009711

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019515467A Active JP6928083B2 (ja) 2016-09-15 2017-09-15 Ｐｄ−１ペプチド阻害剤

Country Status (7)

Country Link
US (4) US10098950B2 (enExample)
EP (2) EP3512536B1 (enExample)
JP (1) JP6928083B2 (enExample)
AU (1) AU2017325866B2 (enExample)
CA (1) CA3036251A1 (enExample)
DK (2) DK3795167T3 (enExample)
WO (1) WO2018053218A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799555B2 (en) 2016-09-15 2020-10-13 Leidos, Inc. PD-1 peptide inhibitors
EP3512536B1 (en) 2016-09-15 2020-11-04 Leidos, Inc. Pd-1 peptide inhibitors
JP7187486B2 (ja) 2017-05-25 2022-12-12 レイドス， インコーポレイテッド Ｐｄ－１およびｃｔｌａ－４二重インヒビターペプチド
WO2019168524A1 (en) * 2018-02-27 2019-09-06 Leidos, Inc. Pd-1 peptide inhibitors
CN111548407B (zh) * 2018-10-30 2021-09-14 北京科优瑞尔生物科技有限公司 一种改进的能与pd-1特异性结合的肿瘤抑制肽及其用途
AU2021283353A1 (en) 2020-06-04 2023-02-02 Leidos, Inc. Immunomodulatory compounds
US11987646B2 (en) 2020-10-12 2024-05-21 Leidos, Inc. Immunomodulatory peptides
CN117177763A (zh) 2021-02-02 2023-12-05 吉奥瓦科斯公司 用于增强疫苗接种期间的t细胞启动的病毒构建体
CN113336824A (zh) * 2021-04-30 2021-09-03 重庆理工大学 一种多肽在作为pd-1/pd-l1蛋白-蛋白相互作用(ppi)调节剂中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057275A1 (en) 1998-05-06 1999-11-11 Pharmacia & Upjohn Company Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
EP2717895A1 (en) 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
EP2822957A1 (en) 2012-03-07 2015-01-14 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
US9422339B2 (en) 2012-03-29 2016-08-23 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds
JP6456305B2 (ja) * 2013-02-22 2019-01-23 キュアバック アーゲー ワクチン接種とｐｄ−１経路の阻害との組み合わせ
EP3185866A1 (en) 2014-08-25 2017-07-05 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
EP3512536B1 (en) 2016-09-15 2020-11-04 Leidos, Inc. Pd-1 peptide inhibitors
CN107383174B (zh) 2017-08-21 2019-01-18 生工生物工程（上海）股份有限公司 一种能与pd-1特异性结合的肿瘤抑制肽及其用途

Also Published As

Publication number Publication date
US20240075131A1 (en) 2024-03-07
DK3795167T3 (da) 2022-08-29
AU2017325866A1 (en) 2019-04-18
US10098950B2 (en) 2018-10-16
AU2017325866B2 (en) 2021-09-09
DK3512536T3 (da) 2020-11-23
US20180185474A1 (en) 2018-07-05
JP2019531293A (ja) 2019-10-31
EP3512536B1 (en) 2020-11-04
US20210000948A1 (en) 2021-01-07
EP3795167B1 (en) 2022-08-03
WO2018053218A1 (en) 2018-03-22
EP3512536A1 (en) 2019-07-24
EP3795167A1 (en) 2021-03-24
CA3036251A1 (en) 2018-03-22
US10799581B2 (en) 2020-10-13
US20180071385A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
JP6928083B2 (ja) Ｐｄ−１ペプチド阻害剤
US12370258B2 (en) PD-1 and CTLA-4 dual inhibitor peptides
US11793856B2 (en) PD-1 peptide inhibitors
JP6998927B2 (ja) 免疫応答を調節するための組成物および方法
JP2022190026A (ja) Ｐｄ－１ペプチド阻害剤
Shen et al. Systemic delivery of mPEG‐masked trispecific T‐cell nanoengagers in synergy with STING agonists overcomes immunotherapy resistance in TNBC and generates a vaccination effect
Li et al. Antigen-clustered nanovaccine achieves long-term tumor remission by promoting B/CD 4 T cell crosstalk
Yang et al. Supramolecular peptide hydrogel epitope vaccine functionalized with CAR-T cells for the treatment of solid tumors
CN107109365A (zh) 多剂量注射用树突状细胞疫苗的制备及用于阻断her2和her3的联合治疗
CN115087661A (zh) Vcx/y肽及其用途
US20230390370A1 (en) Neoantigen vaccines for pancreatic cancer
US20240415828A1 (en) Tlr7 agonist and combinations for cancer treatment
Adedokun et al. Exploring immunotherapeutic strategies for bacterial and viral diseases
KR20250139901A (ko) 최적화된 태그 모이어티

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200915

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210730

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210805

R150 Certificate of patent or registration of utility model

Ref document number: 6928083

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250